From the 2020 Joint Annual Meeting (June 30, 2020)
Presented by Ranjana Arora, MD, MPH
Myeloid malignancies are complex clonal diseases with vast phenotypic and genetic heterogeneity. Molecular profiling is important for diagnosis, treatment, risk stratification, and understanding clonal evolution of these diseases. They usually show greater than one molecular mutation, and the use of multigene next generation sequencing (NGS) panels is important in not only diagnosis of these diseases but also in follow-up for measurable disease assessment.
At the conclusion of this presentation, participants will be able to:
- Discuss clinical relevance of multigene targeted next generation sequencing assay (NGS) in myeloid malignancies.
- Interpret of NGS and its relevance in diagnosis, treatment and prognosis.
- Discuss clonal evolution of myeloid malignancies.
This recorded presentation is P.A.C.E. ® accredited. The instruction level for this activity is Intermediate. One (1) P.A.C.E. ® contact hour and one (1) Florida credit hour in the area of Hematology/Cytogenetics/Molecular Biology will be awarded to participants. ASCLS P.A.C.E.® is accepted by the ASCP/ASCLS/AGT Board of Certification and all states, including Florida and California, as an approved provider of continuing education for recertification and licensure. ASCLS is an approved provider with CE Broker for Florida licensees.
LEVEL OF INSTRUCTION
This intermediate-level program is appropriate for laboratory professionals working in clinical, public health and academic settings.